This report provides detailed analysis of worldwide markets for Fondaparinux from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Fondaparinux market and further lays out an analysis of the factors influencing the supply/demand for Fondaparinux, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Fondaparinux, an injectable blood thinner that fights clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism), is a synthetic pentasaccharide, which is difficult to manufacture on a commercial scale. Although it is a better and safer alternative to pharmaceutical heparins in many cases, its high cost, which results from the difficult and tedious synthesis, is a deterrent for its widespread use.
Fondaparinux injection is used to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg), which can lead to pulmonary embolism (PE; a blood clot in the lung), in people who are having hip surgery, hip or knee replacement, or abdominal surgery. It is also used in along with warfarin (Coumadin, Jantoven) to treat DVT or PE. Fondaparinux injection is in a class of medications called factor Xa inhibitors. It works by decreasing the clotting ability of the blood.
Browse Full Research Report With TOC: http://www.radiantinsights.com/research/global-fondaparinux-market-forecast-and-analysis-2016-2021
Report has been prepared based on the synthesis, analysis, and interpretation of information about the global Fondaparinux market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Fondaparinux market are GSK (UK), Alchemia (Australia), Apotex (Canada), Dr Reddy's (India), ScinoPharm Taiwan (Taiwan), 3SBioing (China), Chase Sun (China), WisMed Pharmaceuticals (China), Kaifeng Pharmaceutical (China), Wuhan Sunrise (China).
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Fondaparinux industry has been provided.
See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com
Fondaparinux, an injectable blood thinner that fights clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism), is a synthetic pentasaccharide, which is difficult to manufacture on a commercial scale. Although it is a better and safer alternative to pharmaceutical heparins in many cases, its high cost, which results from the difficult and tedious synthesis, is a deterrent for its widespread use.
Fondaparinux injection is used to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg), which can lead to pulmonary embolism (PE; a blood clot in the lung), in people who are having hip surgery, hip or knee replacement, or abdominal surgery. It is also used in along with warfarin (Coumadin, Jantoven) to treat DVT or PE. Fondaparinux injection is in a class of medications called factor Xa inhibitors. It works by decreasing the clotting ability of the blood.
Browse Full Research Report With TOC: http://www.radiantinsights.com/research/global-fondaparinux-market-forecast-and-analysis-2016-2021
Report has been prepared based on the synthesis, analysis, and interpretation of information about the global Fondaparinux market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Fondaparinux market are GSK (UK), Alchemia (Australia), Apotex (Canada), Dr Reddy's (India), ScinoPharm Taiwan (Taiwan), 3SBioing (China), Chase Sun (China), WisMed Pharmaceuticals (China), Kaifeng Pharmaceutical (China), Wuhan Sunrise (China).
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Fondaparinux industry has been provided.
See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceutical
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Web: http://www.radiantinsights.com
No comments:
Post a Comment